Turning discoveries into therapies
Here’s what’s in our Pipeline:
*Phase 2a portion of Phase 1/2a clinical trial
**In January 2022, 23andMe elected to take a royalty option on immuno-oncology clinical program GSK’608.
As a result, GSK is now solely responsible for the development of GSK’608.
***50+ programs in the combined therapeutic areas. As of September 2023. Programs include collaborated, 100% owned and royalty interest targets.
Our current clinical programs
23ME-00610
This 23andMe-owned immuno-oncology program is currently in Phase 2 in patients with advanced solid tumors (NCT05199272).
GSK'608 (CD96)
This immuno-oncology program with GSK is currently in Phase 1 in patients with advanced solid tumors (NCT04446351).
Stay in the know
Keep up-to-date with new discoveries and exclusive promotions on our DNA test kits.